Skip to content

Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock

Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02060773
Enrollment
Unknown
Registered
2014-02-12
Start date
2012-12-31
Completion date
2014-02-28
Last updated
2014-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Keywords

Septic shock, Early goal directed therapy, Fluid resuscitation, Hepatic perfusion, Indocyanine Green

Brief summary

To observe the effect of early goal directed therapy (EGDT) on hepatic perfusion in patients with septic shock. Hypothesis: Hepatic perfusion did not improved after EGDT in patients with septic shock.

Detailed description

Objective To observe the effect of early goal directed therapy (EGDT) on hepatic perfusion in patients with septic shock. Methods A prospective observational study was carried out. The eligible patients were treated with the standard procedure of EGDT. The hemodynamic data were recorded. Oxygen metabolism and hepatic function were monitored. Indocyanine clearance test was applied to detect the hepatic perfusion. Hemodynamics, hepatic perfusion, oxygen metabolism and hepatic function were compared before treatment, after EGDT and 24 hours after EGDT.

Interventions

None listed

Sponsors

Zhongda Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. patients with septic shock 2. at least one of the EGDT criteria not achieved 3. informed consent accepted

Exclusion criteria

1. ages below 18 or above 90 2. pregnancy 3. the time elapsed over 24 hours after onset of septic shock 4. chronic liver disease 5. terminal stage of disease 6. brain death 7. other types of shock 8. brain injury 9. allergic to iodine or indocyanine

Design outcomes

Primary

MeasureTime frame
ICG-PDR and R15 before treatment, after EGDT and 24 hours after EGDT.30 hours

Secondary

MeasureTime frameDescription
28 days mortality28 daysFollow up to determine the mortality in 28 days after inclusion

Countries

China

Contacts

Primary ContactXiaohua Qiu, MD
xiaohua0917@163.com0086-025-83262553

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026